Figure 7: A typical EpCAM-expressing target cancer cell (BT-20) after exposure to particles functionalized with: (a) the proper counter-receptor antihuman EpCAM, and (b) anti-mouse IgG, demonstrating the specific binding capabilities of the functionalized particles. All other experimental conditions were identical.